Aptalis’ Ultresa And Viokace Join Crowded Marketplace Of Pancreatic Enzyme Products
This article was originally published in The Pink Sheet Daily
Executive Summary
The fourth and fifth products FDA has approved to treat pancreatic insufficiency join products made by Aptalis, Janssen Pharmaceuticals and Abbott GmbH.
You may also be interested in...
With Ikaria and Aptalis, Private Equity Investors Get Creative To Cash Out
Ikaria shareholders sold the commercial side of that critical care business, but retained a stake in the off-loaded assets. While gastrointestinal and cystic fibrosis company Aptalis turns to an IPO instead of an acquisition.
Deals of the Week: Aptalis For Sale
A report suggests that Aptalis Pharma is on the block, but is the price too high? Also, Quintiles spends some of its IPO war chest on a smaller North Carolina CRO, and Pfizer strikes a diabetes deal with Sanford-Burnham.
Sollpura's Future After No Vote From Panel Might Include More Trials, Adult Indication
FDA's Gastrointestinal Drugs Advisory Committee says in lopsided votes that Lilly's exocrine pancreatic insufficiency drug candidate Sollpura (liprotamase) lacks proof of efficacy.